Eur J Haematol. 2005 Oct;75(4):346-51.
Gopcsa
L, Banyai
A, Jakab
K, Kormos
L, Tamaska
J, Matolcsy
A, Gogolak
P, Rajnavolgyi
E, Paloczi
K.
OBJECTIVES: Accumulating evidence suggests that non-T, non-B cell CD4+CD56+ neoplasms with
lymphoblastic morphology include clinically and immunophenotypically diverse entities.
Although their cells of origin or classification are still controversial several entities
clearly represent a distinct type of neoplasms that are clinically aggressive. METHODS: In
this work we present the immunophenotypic and genotypic features of bone marrow (BM),
peripheral blood (PB), lymph node and skin lymphocytes from a patient diagnosed as
plasmacytoid dendritic cell leukemia involving the skin, BM, PB, lymph nodes, liver and
spleen. For determination of immunophenotypic characteristics of malignant plasmacytoid
dendritic cells 73 monoclonal antibodies detecting lineage markers, chemokine receptors,
cytokine receptors, activation, and co-stimulatory molecules were used. RESULTS AND
CONCLUSION: The malignant cells proved to express CD4+, CD56+ lineage negative leukemia
phenotype characteristically positive for CD36, CD38, CD40, CD45, CD45RA, CD68, CD123,
CD184, HLA-DR, BDCA2, and granzyme-B corresponding to the preplasmacytoid dendritic cell
developmental stage. The presence of CD11a/CD18, CD84, CD91, CD95, alphavbeta5, CDw197,
and the absence of CD52 and CD133 in this case can be regarded as additional features of
malignant cells. Completing the immunophenotypes with multidrug resistance function can
provide additional information for characterizing pDC leukemia.
PMID: 16146542 [PubMed - indexed for MEDLINE]